Agency Information Collection Activities: Submission for OMB Review; Comment Request, 66211-66213 [2019-26001]
Download as PDF
<![CDATA[
Federal Register / Vol. 84, No. 232 / Tuesday, December 3, 2019 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; BRAIN Initiative:
Theories, Models and Methods for Analysis
of Complex Data from the Brain (2020/05).
Date: February 13, 2020.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy Boulevard
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Dennis Hlasta, Ph.D.,
Scientific Review Officer, National Institute
of Biomedical Imaging and Bioengineering,
National Institutes of Health, 6707
Democracy Blvd., Bethesda, MD 20892, (301)
451–4794, dennis.hlasta@nih.gov.
Dated: November 26, 2019.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–26063 Filed 12–2–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
lotter on DSKBCFDHB2PROD with NOTICES
National Institute on Deafness and
Other Communication Disorders;
Notice of Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of
meetings of the National Deafness and
Other Communication Disorders
Advisory Council.
The meetings will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
VerDate Sep<11>2014
18:27 Dec 02, 2019
Jkt 250001
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Deafness and
Other Communication Disorders Advisory
Council.
Date: January 31, 2020.
Closed: 8:30 a.m. to 10:00 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center Building (NSC), Room C
and D, 6001 Executive Boulevard, Rockville,
MD 20852.
Open: 10:00 a.m. to 2:00 p.m.
Agenda: Staff reports on divisional,
programmatical, and special activities.
Place: National Institutes of Health,
Neuroscience Center Building (NSC), Room C
and D, 6001 Executive Boulevard, Rockville,
MD 20852.
Contact Person: Craig A. Jordan, Ph.D.,
Director, Division of Extramural Activities,
NIDCD, NIH, Room 8345, MSC 9670, 6001
Executive Blvd., Bethesda, MD 20892–9670,
301–496–8693, jordanc@nidcd.nih.gov.
Name of Committee: National Deafness and
Other Communication Disorders Advisory
Council.
Date: May 29, 2020.
Closed: 8:30 a.m. to 10:00 a.m.
Agenda: To review and evaluate grant
applications.
Place: Porter Neuroscience Research
Center, Building 35A, Room 620, 35 Convent
Drive, Bethesda, MD 20892.
Open: 10:00 a.m. to 2:00 p.m.
Agenda: staff reports on divisional,
programmatical, and special activities.
Place: Porter Neuroscience Research
Center, Building 35A, Room 620, 35 Convent
Drive, Bethesda, MD 20892.
Contact Person: Craig A. Jordan, Ph.D.,
Director, Division of Extramural Activities,
NIDCD, NIH, Room 8345, MSC 9670, 6001
Executive Blvd., Bethesda, MD 20892–9670,
301–496–8693, jordanc@nidcd.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
66211
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: https://
www.nidcd.nih.gov/about/advisory-council,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.173, Biological Research
Related to Deafness and Communicative
Disorders, National Institutes of Health, HHS)
Dated: November 26, 2019.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–26065 Filed 12–2–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–1243.
Project: Notification of Intent To Use
Schedule III, IV, or V Opioid Drugs for
the Maintenance and Detoxification
Treatment of Opiate Addiction Under
21 U.S.C. 823(g)(2) (OMB No. 0930–
0234 and OMB No. 0930–0369)—
Revision
The Drug Addiction Treatment Act of
2000 (‘‘DATA,’’ Pub. L. 106–310)
amended the Controlled Substances Act
(21 U.S.C. 823(g)(2)) to permit
qualifying practitioners to seek and
obtain waivers to prescribe certain
approved narcotic treatment drugs for
the treatment of opiate addiction. The
legislation set eligibility requirements
and certification requirements as well as
an interagency notification review
process for practitioners who seek
waivers. To implement these provisions,
SAMHSA developed Notification of
Intent Forms that facilitate the
submission and review of notifications.
The forms provide the information
necessary to determine whether
practitioners meets the qualifications for
waivers set forth under the law at the
E:\FR\FM\03DEN1.SGM
03DEN1
66212
Federal Register / Vol. 84, No. 232 / Tuesday, December 3, 2019 / Notices
30-, 100-, and 275-patient limits. This
includes the annual reporting
requirements for practitioners with
waivers for a 275 patient limit. On
October 24, 2018, the Substance Use
Disorder Prevention that Promotes
Opioid Recovery and Treatment for
Patients and Communities (SUPPORT)
Act (Pub. L. 115–71) was signed into
law. Sections 3201–3202 of the
SUPPORT Act made several
amendments to the Controlled
Substances Act regarding office-based
opioid treatment that affords
practitioners greater flexibility in the
provision of medication-assisted
treatment (MAT).
The SUPPORT Act expands the
definition of ‘‘qualifying other
practitioner’’ enabling Clinical Nurse
Specialists, Certified Registered Nurse
Anesthetists, and Certified Nurse
Midwives (CNSs, CRNAs, and CNMs) to
apply for a Drug Addiction Treatment
Act of 2000 (DATA) waiver until
October 1, 2023. It also allows qualified
practitioners (i.e., MDs, DOs, NPs, PAs,
CNSs, CRNAs, and CNMs) who are
board certified in addiction medicine or
addiction psychiatry, -or- practitioners
who provide MAT in a qualified
practice setting, to start treating up to
100 patients in the first year of MAT
practice (as defined in 42 CFR 8.2) with
a waiver.
Further, the SUPPORT Act extends
the ability to treat up to 275 patients to
42 CFR citation
‘‘qualifying other practitioners’’ (i.e.,
NPs, PAs, CNSs, CRNAs, and CNMs) if
they have a waiver to treat up 100
patients for at least one year and
provide medication-assisted treatment
with covered medications (as such
terms are defined under 42 CFR 8.2) in
a qualified practice setting as described
under 42 CFR 8.615. Finally, the
SUPPORT Act also expands how
physicians could qualify for a waiver.
Under the statute now, physicians can
qualify for a waiver if they have
received at least 8 hours of training on
treating and managing opiate-dependent
patients, as listed in the statute if the
physician graduated in good standing
from an accredited school of allopathic
medicine or osteopathic medicine in the
United States during the 5-year period
immediately preceding the date on
which the physician submits to
SAMHSA. In order to expedite the new
provisions of the SUPPORT Act,
SAMHSA sought and received a Public
Health Emergency Paperwork Reduction
Act Waiver. Practitioners may use the
form for four types of notifications: (a)
New Notification to treat up to 30
patients; (b) New Notification, with the
intent to immediately facilitate
treatment of an individual (one) patient;
(c) Second notification of need and
intent to treat up to 100 patients; and (d)
New notification to treat up to 100
patients. Under ‘‘new’’ notifications,
practitioners may make their initial
Estimated
number of
respondents
Purpose of submission
waiver requests to SAMHSA.
‘‘Immediate’’ notifications inform
SAMHSA and the Attorney General of a
practitioner’s intent to prescribe
immediately to facilitate the treatment
of an individual (one) patient under 21
U.S.C. 823(g)(2)(E)(ii). The form collects
data on the following items: Practitioner
name; state medical license number;
medical specialty; and DEA registration
number; address of primary practice
location, telephone and fax numbers;
email address; name and address of
group practice; group practice employer
identification number; names and DEA
registration numbers of group
practitioners; purpose of notification:
New, immediate, or renewal;
certification of qualifying criteria for
treatment and management of opiate
dependent patients; certification of
capacity to provide directly or refer
patients for appropriate counseling and
other appropriate ancillary services;
certification of maximum patient load,
certification to use only those drug
products that meet the criteria in the
law. The form also notifies practitioners
of Privacy Act considerations, and
permits practitioners to expressly
consent to disclose limited information
to the SAMHSA Buprenorphine
Physician and Behavioral Health
Treatment Services locators. The
following table summarizes the
estimated annual burden for the use of
this form.
Burden/
response
(hrs.)
Responses/
respondent
Total burden
(hrs.)
Notification of Intent ..........................................................
Notification to Prescribe Immediately ...............................
Notice to Treat up to 100 patients ...................................
Notice to Treat up to 275 patients ...................................
1,500
50
500
800
1
1
1
1
0.083
0.083
0.04
1
125
4
20
65
Subtotal .....................................................................
2,850
........................
........................
214
Burden Associated with the Final Rule That Increased the Patient Limit
8.620 (a)–(c) .....
8.64 ...................
lotter on DSKBCFDHB2PROD with NOTICES
8.655 .................
Request for Patient Limit Increase * .................................
Request for Patient Limit Increase * .................................
Request for Patient Limit Increase * .................................
Renewal Request for a Patient Limit Increase * ..............
Renewal Request for a Patient Limit Increase * ..............
Renewal Request for a Patient Limit Increase* ...............
Request for a Temporary Patient Increase for an Emergency *.
Request for a Temporary Patient Increase for an Emergency *.
Request for a Temporary Patient Increase for an Emergency *.
517
517
517
260
260
260
10
1
1
1
1
1
1
1
0.5
0.5
0.5
0.5
0.5
0.5
3
259
259
259
130
130
130
30
10
1
3
30
10
1
3
30
Subtotal .....................................................................
2,361
........................
........................
1,256
New Burden Associated with the Final Rule That Outlined the Reporting Requirements
8.635 .................
VerDate Sep<11>2014
Practitioner Reporting Form * ...........................................
‘‘Qualifying Other Practitioner’’ under 21 U.S.C.
823(g)(2)—Nurse Practitioners.
18:27 Dec 02, 2019
Jkt 250001
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
1,350
816
E:\FR\FM\03DEN1.SGM
1
1
03DEN1
3
0.066
4,050
54
66213
Federal Register / Vol. 84, No. 232 / Tuesday, December 3, 2019 / Notices
42 CFR citation
Estimated
number of
respondents
Purpose of submission
‘‘Qualifying Other Practitioner’’ under 21 U.S.C.
823(g)(2)—Physician Assistants.
‘‘Qualifying Other Practitioner’’ under 21 U.S.C.
823(g)(2)—Certified Nurse Specialists.
‘‘Qualifying Other Practitioner’’ under 21 U.S.C.
823(g)(2)—Certified Nurse Mid-Wives.
‘‘Qualifying Other Practitioner’’ under 21 U.SC.
823(g)(2)—Certified Registered Nurse Anesthetists.
Burden/
response
(hrs.)
Responses/
respondent
Total burden
(hrs.)
590
1
0.066
39
590
1
0.066
39
590
1
0.066
39
590
1
0.066
39
Subtotal .....................................................................
4,526
........................
........................
4,260
Total Burden .......................................................
6,561
........................
........................
5,519
Written comments and
recommendations concerning the
proposed information collection should
be sent by January 2, 2020 to the
SAMHSA Desk Officer at the Office of
Information and Regulatory Affairs,
Office of Management and Budget
(OMB). To ensure timely receipt of
comments, and to avoid potential delays
in OMB’s receipt and processing of mail
sent through the U.S. Postal Service,
commenters are encouraged to submit
their comments to OMB via email to:
OIRA_Submission@omb.eop.gov.
Although commenters are encouraged to
send their comments via email,
commenters may also fax their
comments to: 202–395–7285.
Commenters may also mail them to:
Office of Management and Budget,
Office of Information and Regulatory
Affairs, New Executive Office Building,
Room 10102, Washington, DC 20503.
Summer King,
Statistician.
chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–1243.
Project: Confidentiality of Alcohol and
Drug Abuse Patient Records—(OMB No.
0930–0092)—Revision
[FR Doc. 2019–26001 Filed 12–2–19; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Statute (42 U.S.C. 290dd–2) and
regulations (42 CFR part 2) require
federally conducted, regulated, or
directly or indirectly assisted alcohol
and drug abuse programs to keep
alcohol and drug abuse patient records
confidential. Information requirements
are (1) written disclosure to patients
about Federal laws and regulations that
protect the confidentiality of each
patient, and (2) documenting ‘‘medical
personnel’’ status of recipients of a
disclosure to meet a medical emergency.
Annual burden estimates for these
requirements are summarized in the
table below:
ANNUALIZED BURDEN ESTIMATES
Annual
number of
respondents 1
Responses
per
respondent
Total
responses
Hours per
Response
Total hour
burden
Disclosure
42 CFR 2.22 ........................................................................
11,779
163
2 1,920,844
.20
384,169
Recordkeeping
42 CFR 2.51 ........................................................................
11,779
2
23,558
.167
3,934
Total ..............................................................................
11,779
........................
1,944,402
........................
388,103
1 The
lotter on DSKBCFDHB2PROD with NOTICES
number of publicly funded alcohol and drug facilities from SAMHSA’s 2017 National Survey of Substance Abuse Treatment Services (N–
SSATS).
2 The average number of annual treatment admissions from SAMHSA’s 2015–2017 Treatment Episode Data Set (TEDS).
Written comments and
recommendations concerning the
proposed information collection should
be sent by January 2, 2020 to the
SAMHSA Desk Officer at the Office of
Information and Regulatory Affairs,
Office of Management and Budget
(OMB). To ensure timely receipt of
VerDate Sep<11>2014
18:27 Dec 02, 2019
Jkt 250001
comments, and to avoid potential delays
in OMB’s receipt and processing of mail
sent through the U.S. Postal Service,
commenters are encouraged to submit
their comments to OMB via email to:
OIRA_Submission@omb.eop.gov.
Although commenters are encouraged to
send their comments via email,
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
commenters may also fax their
comments to: 202–395–7285.
Commenters may also mail them to:
Office of Management and Budget,
Office of Information and Regulatory
E:\FR\FM\03DEN1.SGM
03DEN1
]]>Agencies
[Federal Register Volume 84, Number 232 (Tuesday, December 3, 2019)]
[Notices]
[Pages 66211-66213]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-26001]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Agency Information Collection Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and Mental Health Services
Administration (SAMHSA) will publish a summary of information
collection requests under OMB review, in compliance with the Paperwork
Reduction Act (44 U.S.C. chapter 35). To request a copy of these
documents, call the SAMHSA Reports Clearance Officer on (240) 276-1243.
Project: Notification of Intent To Use Schedule III, IV, or V Opioid
Drugs for the Maintenance and Detoxification Treatment of Opiate
Addiction Under 21 U.S.C. 823(g)(2) (OMB No. 0930-0234 and OMB No.
0930-0369)--Revision
The Drug Addiction Treatment Act of 2000 (``DATA,'' Pub. L. 106-
310) amended the Controlled Substances Act (21 U.S.C. 823(g)(2)) to
permit qualifying practitioners to seek and obtain waivers to prescribe
certain approved narcotic treatment drugs for the treatment of opiate
addiction. The legislation set eligibility requirements and
certification requirements as well as an interagency notification
review process for practitioners who seek waivers. To implement these
provisions, SAMHSA developed Notification of Intent Forms that
facilitate the submission and review of notifications. The forms
provide the information necessary to determine whether practitioners
meets the qualifications for waivers set forth under the law at the
[[Page 66212]]
30-, 100-, and 275-patient limits. This includes the annual reporting
requirements for practitioners with waivers for a 275 patient limit. On
October 24, 2018, the Substance Use Disorder Prevention that Promotes
Opioid Recovery and Treatment for Patients and Communities (SUPPORT)
Act (Pub. L. 115-71) was signed into law. Sections 3201-3202 of the
SUPPORT Act made several amendments to the Controlled Substances Act
regarding office-based opioid treatment that affords practitioners
greater flexibility in the provision of medication-assisted treatment
(MAT).
The SUPPORT Act expands the definition of ``qualifying other
practitioner'' enabling Clinical Nurse Specialists, Certified
Registered Nurse Anesthetists, and Certified Nurse Midwives (CNSs,
CRNAs, and CNMs) to apply for a Drug Addiction Treatment Act of 2000
(DATA) waiver until October 1, 2023. It also allows qualified
practitioners (i.e., MDs, DOs, NPs, PAs, CNSs, CRNAs, and CNMs) who are
board certified in addiction medicine or addiction psychiatry, -or-
practitioners who provide MAT in a qualified practice setting, to start
treating up to 100 patients in the first year of MAT practice (as
defined in 42 CFR 8.2) with a waiver.
Further, the SUPPORT Act extends the ability to treat up to 275
patients to ``qualifying other practitioners'' (i.e., NPs, PAs, CNSs,
CRNAs, and CNMs) if they have a waiver to treat up 100 patients for at
least one year and provide medication-assisted treatment with covered
medications (as such terms are defined under 42 CFR 8.2) in a qualified
practice setting as described under 42 CFR 8.615. Finally, the SUPPORT
Act also expands how physicians could qualify for a waiver. Under the
statute now, physicians can qualify for a waiver if they have received
at least 8 hours of training on treating and managing opiate-dependent
patients, as listed in the statute if the physician graduated in good
standing from an accredited school of allopathic medicine or
osteopathic medicine in the United States during the 5-year period
immediately preceding the date on which the physician submits to
SAMHSA. In order to expedite the new provisions of the SUPPORT Act,
SAMHSA sought and received a Public Health Emergency Paperwork
Reduction Act Waiver. Practitioners may use the form for four types of
notifications: (a) New Notification to treat up to 30 patients; (b) New
Notification, with the intent to immediately facilitate treatment of an
individual (one) patient; (c) Second notification of need and intent to
treat up to 100 patients; and (d) New notification to treat up to 100
patients. Under ``new'' notifications, practitioners may make their
initial waiver requests to SAMHSA. ``Immediate'' notifications inform
SAMHSA and the Attorney General of a practitioner's intent to prescribe
immediately to facilitate the treatment of an individual (one) patient
under 21 U.S.C. 823(g)(2)(E)(ii). The form collects data on the
following items: Practitioner name; state medical license number;
medical specialty; and DEA registration number; address of primary
practice location, telephone and fax numbers; email address; name and
address of group practice; group practice employer identification
number; names and DEA registration numbers of group practitioners;
purpose of notification: New, immediate, or renewal; certification of
qualifying criteria for treatment and management of opiate dependent
patients; certification of capacity to provide directly or refer
patients for appropriate counseling and other appropriate ancillary
services; certification of maximum patient load, certification to use
only those drug products that meet the criteria in the law. The form
also notifies practitioners of Privacy Act considerations, and permits
practitioners to expressly consent to disclose limited information to
the SAMHSA Buprenorphine Physician and Behavioral Health Treatment
Services locators. The following table summarizes the estimated annual
burden for the use of this form.
----------------------------------------------------------------------------------------------------------------
Estimated Burden/
42 CFR citation Purpose of number of Responses/ response Total burden
submission respondents respondent (hrs.) (hrs.)
----------------------------------------------------------------------------------------------------------------
Notification of 1,500 1 0.083 125
Intent.
Notification to 50 1 0.083 4
Prescribe
Immediately.
Notice to Treat up 500 1 0.04 20
to 100 patients.
Notice to Treat up 800 1 1 65
to 275 patients.
---------------------------------------------------------------
Subtotal......... 2,850 .............. .............. 214
----------------------------------------------------------------------------------------------------------------
Burden Associated with the Final Rule That Increased the Patient Limit
----------------------------------------------------------------------------------------------------------------
8.620 (a)-(c)............. Request for Patient 517 1 0.5 259
Limit Increase *.
Request for Patient 517 1 0.5 259
Limit Increase *.
Request for Patient 517 1 0.5 259
Limit Increase *.
8.64...................... Renewal Request for 260 1 0.5 130
a Patient Limit
Increase *.
Renewal Request for 260 1 0.5 130
a Patient Limit
Increase *.
Renewal Request for 260 1 0.5 130
a Patient Limit
Increase*.
8.655..................... Request for a 10 1 3 30
Temporary Patient
Increase for an
Emergency *.
Request for a 10 1 3 30
Temporary Patient
Increase for an
Emergency *.
Request for a 10 1 3 30
Temporary Patient
Increase for an
Emergency *.
---------------------------------------------------------------
Subtotal......... 2,361 .............. .............. 1,256
----------------------------------------------------------------------------------------------------------------
New Burden Associated with the Final Rule That Outlined the Reporting Requirements
----------------------------------------------------------------------------------------------------------------
8.635..................... Practitioner 1,350 1 3 4,050
Reporting Form *.
``Qualifying Other 816 1 0.066 54
Practitioner''
under 21 U.S.C.
823(g)(2)--Nurse
Practitioners.
[[Page 66213]]
``Qualifying Other 590 1 0.066 39
Practitioner''
under 21 U.S.C.
823(g)(2)--Physicia
n Assistants.
``Qualifying Other 590 1 0.066 39
Practitioner''
under 21 U.S.C.
823(g)(2)--Certifie
d Nurse Specialists.
``Qualifying Other 590 1 0.066 39
Practitioner''
under 21 U.S.C.
823(g)(2)--Certifie
d Nurse Mid-Wives.
``Qualifying Other 590 1 0.066 39
Practitioner''
under 21 U.SC.
823(g)(2)--Certifie
d Registered Nurse
Anesthetists.
---------------------------------------------------------------
Subtotal......... 4,526 .............. .............. 4,260
---------------------------------------------------------------
Total Burden... 6,561 .............. .............. 5,519
----------------------------------------------------------------------------------------------------------------
Written comments and recommendations concerning the proposed
information collection should be sent by January 2, 2020 to the SAMHSA
Desk Officer at the Office of Information and Regulatory Affairs,
Office of Management and Budget (OMB). To ensure timely receipt of
comments, and to avoid potential delays in OMB's receipt and processing
of mail sent through the U.S. Postal Service, commenters are encouraged
to submit their comments to OMB via email to:
[email protected]. Although commenters are encouraged to send
their comments via email, commenters may also fax their comments to:
202-395-7285. Commenters may also mail them to: Office of Management
and Budget, Office of Information and Regulatory Affairs, New Executive
Office Building, Room 10102, Washington, DC 20503.
Summer King,
Statistician.
[FR Doc. 2019-26001 Filed 12-2-19; 8:45 am]
BILLING CODE 4162-20-P
